Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: A Pediatric Blood and Marrow Transplant Consortium study

Blood

Volumn 114, Issue 20, 2009, Pages 4354-4360

  Jacobsohn, David A ^a   Gilman, Andrew L ^b   Rademaker, Alfred ^a   Browning, Brittan ^c   Grimley, Michael ^d   Lehmann, Leslie ^e   Nemecek, Eneida R ^f   Thormann, Kimberly ^a   Schultz, Kirk R ^g   Vogelsang, Georgia B ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Levine Chidren's Hospital   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d Methodist Hospital   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTOSTATIN; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFANT; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; PANCREATITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCLEROSIS; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS INFECTION; CHRONIC DISEASE; GRAFT VERSUS HOST REACTION; MULTICENTER STUDY; NEOPLASM; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT; MALE; NEOPLASMS; PENTOSTATIN; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 73349089953     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-224840     Document Type: Article

References (36)

1. Klein AK, Patel DD, Gooding ME, et al. T-Cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001;7(8):454-466.
2. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57(2):267-276.
3. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51.
4. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(1):47-55.
5. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73(1):56-61.
6. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762.
7. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074- 3080.
8. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-2674.
9. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25(10):1067-1071.
10. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol. 2003;122(1):118-127.
11. Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion. 2007;47(12):2276-2289.
12. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994;330(10):691-697.
13. Higman M, Vogelsang GB, Chen A. Pentostatin-pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother. 2004;5(12):2605-2613.
14. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709-718.
15. Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23(12):2661-2668.
16. Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol. 2007;25(27):4255-4261.
17. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
18. Gilman AL, Serody J. Diagnosis and treatment of chronic graft-versus-host disease. Semin Hematol. 2006;43(1):70-80.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
20. SAS Institute Inc. SAS Online Doc: Statistics, Version 9.1.3. Cary, NC: SAS Institute Inc; 2004.
21. Greinix HT, Antin JH. Salvage therapy in chronic graft versus host disease. In: Vogelsang GB, Pavletic S, eds. Chronic Graft Versus Host Disease: Interdisciplinary Management. New York, NY: Cambridge; 2009.
22. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, IV: Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-266.
23. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215.
24. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78-84.
25. Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43(2):149-153.
26. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, VI: Design of Clinical Trials Working Group Report. Biol Blood Marrow Transplant. 2006;12(5):491-505.
27. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506.
28. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114(3):719-722.
29. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074-5082.
30. Page KM, Mendizabal AM, Prasad VK, et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2008;14(10):1108-1117.
31. Sanz J, Arriaga F, Montesinos P, et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant. 2007;39(9):555-561.
32. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood. 2008;111(6):3276-3285.
33. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865-3874.
34. Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;100(4):1192-1200.
35. Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007;13(10):1145-1152.
36. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102(3):802-809.